[{"Assets_0_Q3_USD":176176000.0,"CommonStockSharesOutstanding_0_Q3_shares":30991060.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-73563000.0,"NetIncomeLoss_1_Q3_USD":-32740000.0,"NetIncomeLoss_3_Q3_USD":-94187000.0,"StockholdersEquity_0_Q3_USD":146328000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1628000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":6422000.0,"Ticker":"ACRS","CIK":"1557746","name":"ACLARIS THERAPEUTICS, INC.","OfficialName":"Aclaris Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1075670582.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20181106"}]